Literature DB >> 23034071

Molecular epidemiology of Acinetobacter baumannii and Acinetobacter nosocomialis in Germany over a 5-year period (2005-2009).

X Schleicher1, P G Higgins, H Wisplinghoff, B Körber-Irrgang, M Kresken, H Seifert.   

Abstract

To investigate the species distribution within the Acinetobacter calcoaceticus-Acinetobacter baumannii complex and the molecular epidemiology of A. baumannii and Acinetobacter nosocomialis, 376 Acinetobacter isolates were collected prospectively from hospitalized patients at 15 medical centres in Germany during three surveillance studies conducted over a 5-year period. Species identification was performed by molecular methods. Imipenem minimum inhibitory concentrations (MIC) were determined by broth microdilution. The prevalence of the most common carbapenemase-encoding genes was investigated by oxacillinase (OXA) -multiplex polymerase chain reaction (PCR). The molecular epidemiology was investigated by repetitive sequence-based PCR (rep-PCR; DiversiLab™). Acinetobacter pittii was the most prevalent Acinetobacter species (n = 193), followed by A. baumannii (n = 140), A. calcoaceticus (n = 10) and A. nosocomialis (n = 8). The majority of A. baumannii was represented by sporadic isolates (n = 70, 50%) that showed unique rep-PCR patterns, 25 isolates (18%) clustered with one or two other isolates, and only 45 isolates (32%) belonged to one of the previously described international clonal lineages. The most prevalent clonal lineage was international clone (IC) 2 (n = 34) and IC 1 (n = 6). According to CLSI, 25 A. baumannii isolates were non-susceptible to imipenem (MIC ≥ 8 mg/L), all of which produced an OXA-58-like or OXA-23-like carbapenemase. The rate of imipenem susceptibility among A. baumannii isolates decreased from 96% in 2005 to 76% in 2009. All other Acinetobacter isolates were susceptible to imipenem. The population structure of carbapenem-susceptible A. baumannii in Germany is highly diverse. Imipenem non-susceptibility was strongly associated with the clonal lineages IC 2 and IC 1. These data underscore the high clonality of carbapenem-resistant A. baumannii isolates.
© 2012 The Authors. Clinical Microbiology and Infection © 2012 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Keywords:  Acinetobacter calcoaceticus-Acinetobacter baumannii complex; Acinetobacter pittii; Diversilab; carbapenemase; clonal lineage; international clone; oxacillinase; repetitive sequence-based polymerase chain reaction typing

Mesh:

Substances:

Year:  2012        PMID: 23034071     DOI: 10.1111/1469-0691.12026

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  34 in total

1.  First Report of the Carbapenemase Gene blaOXA-499 in Acinetobacter pittii.

Authors:  Roshan D'Souza; Naina Adren Pinto; Paul G Higgins; Insik Hwang; Dongeun Yong; Jongrak Choi; Kyoungwon Lee; Yunsop Chong
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  A Prospective Study of Acinetobacter baumannii Complex Isolates and Colistin Susceptibility Monitoring by Mass Spectrometry of Microbial Membrane Glycolipids.

Authors:  Lisa M Leung; Christi L McElheny; Francesca M Gardner; Courtney E Chandler; Sarah L Bowler; Roberta T Mettus; Caressa N Spychala; Erin L Fowler; Belita N A Opene; Robert A Myers; David R Goodlett; Yohei Doi; Robert K Ernst
Journal:  J Clin Microbiol       Date:  2019-02-27       Impact factor: 5.948

3.  Characterization of blaOXA-143 variants in Acinetobacter baumannii and Acinetobacter pittii.

Authors:  Esther Zander; Rémy A Bonnin; Harald Seifert; Paul G Higgins
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

4.  Outer membrane Protein A plays a role in pathogenesis of Acinetobacter nosocomialis.

Authors:  Sang Woo Kim; Man Hwan Oh; So Hyun Jun; Hyejin Jeon; Seung Il Kim; Kwangho Kim; Yoo Chul Lee; Je Chul Lee
Journal:  Virulence       Date:  2016-01-13       Impact factor: 5.882

5.  Light Modulates Important Pathogenic Determinants and Virulence in ESKAPE Pathogens Acinetobacter baumannii, Pseudomonas aeruginosa, and Staphylococcus aureus.

Authors:  M R Tuttobene; J F Pérez; E S Pavesi; B Perez Mora; D Biancotti; P Cribb; M Altilio; G L Müller; H Gramajo; G Tamagno; M S Ramírez; L Diacovich; M A Mussi
Journal:  J Bacteriol       Date:  2021-02-08       Impact factor: 3.490

6.  Acinetobacter pittii from Companion Animals Coharboring blaOXA-58, the tet(39) Region, and Other Resistance Genes on a Single Plasmid.

Authors:  Peter Klotz; Lisa Jacobmeyer; Ursula Leidner; Ivonne Stamm; Torsten Semmler; Christa Ewers
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

7.  A case of IMP-4-, OXA-421-, OXA-96-, and CARB-2-producing Acinetobacter pittii sequence type 119 in Australia.

Authors:  Witchuda Kamolvit; Petra Derrington; David L Paterson; Hanna E Sidjabat
Journal:  J Clin Microbiol       Date:  2014-11-26       Impact factor: 5.948

Review 8.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

9.  Globally expanding carbapenemase finally appears in Spain: nosocomial outbreak of acinetobacter baumannii producing plasmid-encoded OXA-23 in Barcelona, Spain.

Authors:  Noraida Mosqueda; Paula Espinal; Clara Cosgaya; Sergio Viota; Virginia Plasensia; Francisco Alvarez-Lerma; Milagro Montero; Julià Gómez; Juan Pablo Horcajada; Jordi Vila; Ignasi Roca
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

10.  Clinical outcomes of hospital-acquired infection with Acinetobacter nosocomialis and Acinetobacter pittii.

Authors:  Sarunyou Chusri; Virasakdi Chongsuvivatwong; Jesabel I Rivera; Kachornsakdi Silpapojakul; Kamonnut Singkhamanan; Edward McNeil; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2014-05-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.